EUVIMEDEUVIMED entdecken
Open Access

Single-day nonactivated IL-18–armed CAR T cells establish a durable, stemlike state with enhanced persistence

Joseph S Durgin, Shin Seo iD, Shadab Kazmi iD, Bakir Valentic iD, Chloe Leff iD, Martina Markovska iD, Xiaoling Jin, Feng Shen, Abdulla Berjis, Nandana Mukherjee, Ashwin Sannecy iD, Gabriela Plesa iD und 6 weitere

Blood · 2026

DOI: 10.1182/blood.2026033460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2026. Verfasst von Joseph S Durgin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Michigan, Ann Arbor, MI. Hauptthemen laut MEDLINE: Interleukin-18, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell malignancies, yet challenges including manufacturing delays, T-cell exhaustion, and limited persistence impede broader clinical success. Here, we report the single-day production of nonactivated CAR T cells engineered to secrete interleukin-18 (IL-18), a proinflammatory cytokine that enhances T-cell function. These nonactivated CART19-IL-18 cells (IL-18–secreting anti-CD19 CAR T cells) exhibit robust antitumor efficacy across xenograft models of lymphoma, leukemia, and pancreatic cancer. IL-18 expression enhances the functional advantages of naïve-like nonactivated CAR T cells, resulting in improved persistence, metabolic fitness, and resistance to exhaustion. Single-cell transcriptomic analysis revealed upregulation of IL7R, KLF2, and MCL1, alongside suppression of inhibitory checkpoint genes such as PDCD1, TOX, and HAVCR2. Metabolomic profiling demonstrated enhanced mitochondrial bioenergetics, with increased spare respiratory capacity and accumulation of α-ketoglutarate, malate, and spermine. Functional in vitro and in vivo profiling demonstrated enhanced per-cell cytotoxicity and in vivo durability. We complemented these studies with single-cell transcriptomic and metabolomic analyses to define CAR T-cell biological states beyond what is captured by xenograft tumor clearance. This IL-18–enhanced, activation-free CAR T-cell product offers a clinically actionable platform with the potential to reduce vein-to-vein time while improving product potency and persistence, providing a rationale for clinical testing in patients with tumors refractory to standard CAR T-cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-18Receptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesHumansAnimalsMiceXenograft Model Antitumor AssaysT-Cell ExhaustionMice, SCIDFemale

Substanzen

Interleukin-18Receptors, Chimeric AntigenIL18 protein, human

Autor:innen und Institutionen

  • Department of Dermatology, University of Michigan, Ann Arbor, MI.
  • Department of Pathology, University of Michigan, Ann Arbor, MI.
  • Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Department of Bioengineering, University of Pennsylvania, Philadelphia, PA.
  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

ORCID-Profile: Shin Seo, Shadab Kazmi, Bakir Valentic, Chloe Leff, Martina Markovska, Ashwin Sannecy, Gabriela Plesa, Khatuna Gabunia, John Scholler, Roddy S O'Connor, Carl H June

Förderung

  • NCI NIH HHS
  • NIAMS NIH HHS

Zitieren

APA

Durgin, J. S., Seo, S., Kazmi, S., Valentic, B., Leff, C., Markovska, M., Jin, X., Shen, F., Berjis, A., Mukherjee, N., Sannecy, A., Plesa, G., Gabunia, K., Scholler, J., Gill, S. I., O'Connor, R. S., June, C. H., & Ghassemi, S. (2026). Single-day nonactivated IL-18–armed CAR T cells establish a durable, stemlike state with enhanced persistence. Blood. https://doi.org/10.1182/blood.2026033460

Vancouver

Durgin JS, Seo S, Kazmi S, Valentic B, Leff C, Markovska M, et al. Single-day nonactivated IL-18–armed CAR T cells establish a durable, stemlike state with enhanced persistence. Blood. 2026. doi:10.1182/blood.2026033460

BibTeX
@article{Durgin2026,
  author = {Durgin, Joseph S and Seo, Shin and Kazmi, Shadab and Valentic, Bakir and Leff, Chloe and Markovska, Martina and Jin, Xiaoling and Shen, Feng and Berjis, Abdulla and Mukherjee, Nandana and Sannecy, Ashwin and Plesa, Gabriela and Gabunia, Khatuna and Scholler, John and Gill, Saar I and O'Connor, Roddy S and June, Carl H and Ghassemi, Saba},
  title = {Single-day nonactivated IL-18–armed CAR T cells establish a durable, stemlike state with enhanced persistence},
  journal = {Blood},
  year = {2026},
  doi = {10.1182/blood.2026033460}
}
Kostenlos starten →